Acer Therapeutics Inc ACER shares were trading down more than 75% Tuesday after it received a letter from the Food and Drug Administration regarding its drug application for Edsivo in the treatment of vascular Ehlers-Danlos syndrome.
The FDA said it is necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.
The rare disorder is caused by a gene mutation affecting a major protein, which causes weakness in vessel walls and hollow organs.
Acer Therapeutics plans to request a meeting to discuss the FDA’s response.
“We remain committed to working closely with the FDA to fully understand its response,” CEO Chris Schelling said in a statement. “We expect to respond to the FDA in the third quarter of this year."
Acer Therapeutics shares were down 77.36% at $4.36 at the time of publication.
Related Links:
Genfit Partners With Terns Pharma To Develop, Commercialize Elafibranor In China
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
